"Anti cancer miracle drug" may cause heart disease? Zhongshan Hospital Releases National First Clinical Reference Book
2024-06-28
Nowadays, new types of anti-cancer drugs are emerging one after another, and the survival rate of cancer patients is constantly increasing. However, the cardiac toxicity of anti-tumor drugs has also become a focus and hotspot on a global scale. On the occasion of the 18th Oriental Cardiology Conference and the World Cardiology Conference, the third "Clinical Diagnosis and Treatment Course for Cardiovascular Adverse Reactions Related to Immune Checkpoint Inhibitors" was launched, and the first clinical reference book focusing on ICIs related myocarditis in China, "Immune Checkpoint Inhibitor Related myocarditis - From Basic to Clinical," was released. The conference was jointly organized by Zhongshan Hospital affiliated with Fudan University, Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, Fudan University Cancer Hospital, Oriental Cardiology Conference "Tumor Cardiology Forum", Shanghai Clinical Medicine Editorial Department, and Shanghai Jianmeng Medical Technology Service Center. According to statistics, in 2022, 4.8247 million new cancer patients were diagnosed in China, with an average of 9.2 people diagnosed with cancer per minute. It is worth noting that many long-term clinical follow-up studies on some tumor species, such as breast cancer, confirmed that the final mortality statistics showed that cardiovascular disease even exceeded the tumor itself. In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has made significant breakthroughs in the field of tumor treatment. However, this "anti-cancer miracle drug" may cause immune myocarditis, with a mortality rate of 39.7-66%! The resulting problems have become a huge challenge for medical staff in cardiology and oncology related departments. Fan Jia, an academician of the CAS Member and president of the Sun Yat sen Hospital affiliated to Fudan University, said that Sun Yat sen Hospital had opened the first multidisciplinary oncology and cardiology (MDT) clinic in East China in April 2018. This team is an integral part of the Fudan Zhongshan Cancer Prevention and Treatment Center, committed to providing more comprehensive and accurate diagnosis and treatment services for cancer patients through interdisciplinary cooperation. Ge Junbo, an academician of the CAS Member and director of the Department of Cardiology of Sun Yat sen Hospital affiliated to Fudan University, said that this class gave detailed explanations on various cardiovascular diseases related to inhibitors at immune checkpoints, and strengthened exchanges and cooperation between cardiovascular and tumor related departments, hoping to jointly improve the level of diagnosis and treatment of cardiovascular adverse reactions related to inhibitors at immune checkpoints and bring more safe and effective treatment programs to patients. Fang Min, the director of Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, believes that the cardiac toxic side effects caused by immune checkpoint inhibitors exhibit diversity and complexity, and it is necessary to strengthen clinical multidisciplinary collaboration to ensure that patients receive optimal and reasonable treatment. Traditional Chinese medicine has unique advantages in overall regulation, detoxification and efficacy enhancement, regulation of immune microenvironment, and control of cytokine storms. Exploring the clinical efficacy and mechanism of traditional Chinese medicine from both clinical and mechanistic perspectives can provide new avenues for the treatment of immune checkpoint inhibitor associated myocarditis. Professor Zhou Jian, Executive Vice President of Zhongshan Hospital, hopes that this learning class can provide students with the latest clinical diagnosis and treatment perspectives, in order to further improve their clinical diagnosis and treatment level for patients with tumors and cardiovascular diseases. "Through demonstration and guidance, we will promote Shanghai's advanced diagnosis and treatment experience to the whole country." "Born a tumor, but fell in the heart?" This statement is not a alarmist statement for cancer patients. Under the guidance and support of Academician Ge Junbo, Professor Cheng Leilei, the director of the oncology and cardiology sub specialty at Zhongshan Hospital, led a multidisciplinary team in oncology and cardiology to write and publish the first concise clinical practice summary of oncology and cardiology in China, as well as the first and currently only multidisciplinary science popularization video series on oncology and cardiology in China. In response to the hot and difficult topic of immune checkpoint inhibitor related myocarditis worldwide, the team organized the development of the first clinical reference book focusing on ICIs related myocarditis in China, titled "Immune checkpoint inhibitor related myocarditis - from basic to clinical". Experts such as Wang Xiaolong, Director of the Cardiology Department at Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, and Zhang Jian, Director of the Phase I Clinical Research Ward at Fudan University Affiliated Cancer Hospital, all mentioned that with the continuous promotion and application of immune checkpoint inhibitors, more oncology and cardiovascular medical staff are needed to pay attention to cardiac indicators before, during, and after treatment for cancer patients. Once drug related toxicity is detected, timely diagnosis and treatment can be carried out to strive for higher survival rates and better quality of life for cancer patients. The course of this study attracted over a hundred experts from all over the country to attend. The course content was jointly designed by the multidisciplinary team of Fudan Zhongshan Cancer and Cardiology, Shanghai University of Traditional Chinese Medicine Affiliated Shuguang Hospital, Fudan University Affiliated Cancer Hospital, and others. In order to share the advanced experience of Shanghai, the multidisciplinary team of oncology and cardiology at Zhongshan Hospital has opened the "Clinical Diagnosis and Treatment Course for Immune Checkpoint Inhibitor Related Myocarditis" for the first time in China since 2022, inviting medical colleagues from remote areas to explore and learn together. All courses are open to colleagues nationwide for free, and so far, the online and offline audience has exceeded 80000 people. (Lai Xin She)
Edit：Xiong Dafei Responsible editor：Li Xiang
Source：WHB
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com
Recommended Reading Change it 
Home
